Medicure Inc. (TSXV: MPH, OTC PINK: MCUJF) presented the design, rationale, and baseline data from its MEND-PNPO Phase 3 clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE